Previous 10 | Next 10 |
The following slide deck was published by 111, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: 111, Inc. 2021 Q2 - Results - Earnings Call Presentation
111 (YI -6.6%) reports Q2 revenue of $468.4M, representing an increase of 86.5% Y/Y, marking the 12th consecutive quarter of year-over-year growth. Operating expense increased 82.2% Y/Y. Loss from operations increased to $29.2M which was 6.2% as a percentage of net revenues. Ca...
111, Inc. Announces Second Quarter 2021 Unaudited Financial Results PR Newswire SHANGHAI , Aug. 27, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting pat...
Gainers: Locust Walk Acquisition (NASDAQ:LWACU) +159%. Aditxt (NASDAQ:ADTX) +72%. Takung Art (NYSE:TKAT) +56%. Jiayin (NASDAQ:JFIN) +26%. Universal Security Instruments (NYSE:UUU) +23%. ScanSource (NASDAQ:SCSC) +18%. Lantern Pharma (NASDAQ:LTRN) +18%. InnSuites Hospitality Trust (NYSE:I...
Gainers: Aditxt ADTX +76%, BioLife Solutions (NASDAQ:BLFS) +15%, Virpax Pharmaceuticals (NASDAQ:VRPX) +10%, Flexion Therapeutics FLXN +9%, Rafael (NYSE:RFL) +7%. Losers: Cassava Sciences SAVA -22%, 111 (NASDAQ:YI) -15%, Owlet (NYSE:OWLT) ...
111 (NASDAQ: YI) is a severely undervalued telepharmacy that is rapidly expanding across all of China. The stock trades at less than 0.4 times revenue with a market cap of less than $500 million, despite showing no signs of stalling. It is quite obvious investors are heavily d...
111, Inc. is a mobile healthcare platform, which sells drugs and healthcare services. The company looks undervalued especially after the recent unjustified sell-off in its shares triggered by China's continued regulatory crackdown on tech stocks. 111, Inc. though, does not represe...
111, Inc. Deepens Partnership with Bayer Healthcare PR Newswire SHANGHAI , Aug. 16, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medic...
111 to Announce Second Quarter 2021 Unaudited Financial Results on August 27, 2021 -Conference Call to Follow PR Newswire SHANGHAI , Aug. 9, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform com...
111 (YI -2.9%) has announced a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals, an innovative drug R&D and production company. The agreement will allow 111 and Zelgen to build an innovative out-of-hospital, virtual management platform for liver cancer patients t...
News, Short Squeeze, Breakout and More Instantly...
111 Announces Appointment of New Auditor PR Newswire SHANGHAI , July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digi...
111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024 PR Newswire SHANGHAI July 17, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the ...
111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility PR Newswire SHANGHAI , June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare plat...